Reports Q1 revenue $2.4M, consensus $2.6M. “I am pleased to announce the expansion of the Curis (CRIS) Executive Team with the addition of Dr. Ahmed Hamdy as our Chief Medical Officer. Hamdy is a well-known and respected leader in the industry and brings a wealth of experience as CMO of Pharmacyclics, CMO and CEO of Acerta, and CEO of Vincerx. We look forward to his contributions to Curis. Also, as we announced at the end of March, we have made exciting progress with both the FDA and EMA on the potential for accelerated approval of emavusertib in R/R PCNSL. We are currently enrolling patients in the TakeAim Lymphoma study to enable accelerated approval filings in both the EU and US. We expect to provide additional data for both BTK-naive and BTK-experienced patients from the TakeAim Lymphoma study at ASH later this year,” said James Dentzer, President and CEO of Curis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRIS:
- Curis’s Strategic Advancements and Promising Outlook in IRAK4 Inhibitor Space Drive Buy Rating
- Curis’s Promising Clinical Developments and Strategic Path to Accelerated Approval Boost Buy Rating
- Curis Inc. Reports Q4 2024 Progress and Financials
- Curis Inc. Earnings Call: Progress Amidst Challenges
- Curis price target lowered to $16 from $20 at H.C. Wainwright